Head-To-Head Analysis: Aditxt (NASDAQ:ADTX) & Royalty Pharma (NASDAQ:RPRX)

Aditxt (NASDAQ:ADTX) and Royalty Pharma (NASDAQ:RPRX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Aditxt and Royalty Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1	0	0	0	1.00
Royalty Pharma	0	0	8	0	3.00

Royalty Pharma has a consensus price target of $61.57, indicating a potential downside of 3.42%. Given Royalty Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than Aditxt.

Risk & Volatility

Aditxt has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Insider and Institutional Ownership

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 54.3% of Royalty Pharma shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 18.8% of Royalty Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aditxt and Royalty Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Royalty Pharma	32.14%	30.01%	14.91%

Valuation & Earnings

This table compares Aditxt and Royalty Pharma”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14,336.00	0.03	-$41.71 million	($100,788.35)	-0.00
Royalty Pharma	$2.38 billion	15.41	$770.95 million	$1.45	43.97

Royalty Pharma has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Royalty Pharma beats Aditxt on 13 of the 14 factors compared between the two stocks.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.